Research
Andrea Staratschek-Jox, Priv. Doz. Dr. med.Group leader
|
| 1993-1994 | Internship (ÄIP), Medical school University of Cologne, Department I of Internal Medicine, Germany |
| 1994-1999 | Assistant physician and post doctoral fellow, Medical school University of Cologne, Department I of Internal Medicine, Germany |
| 1998-1999 | Assistant physician, Institute of Human Genetics, University of Bonn, Germany |
| 1999-2001 | Assistant physician and post doctoral fellow, Institute of Human Genetics, University of Bremen, Germany |
| 2001 | postdoctoral lecture qualification in Experimental Internal Medicine (Habilitation), University of Cologne, Germany |
| 2001-2004 | Leading scientist molecular biology, ATABIS GmbH, Cologne, Germany |
| 2004-2008 | Assistant physician and senior scientist, Medical school University of Cologne, Department I of Internal Medicine, Germany |
| since 2008 | Assistant Professor / Lecturer and group leader “Functional Genomics” Life & Medical Sciences Institute (LIMES), University of Bonn, Germany |
Research Interests
Since decades cancer emerged as a serious issue of high incidence which frequently results in lethal outcome. As a reason clinically undetected cancer formation occurs during a latency period of several years while clinical symptoms often present only at late stages of the disease when curative intervention is almost impossible. During this time frame somatic mutation accumulate within the cancer genome enabling the cell to overcome pro-apoptotic stimuli as well as immune surveillance. Moreover the establishing tumor microenvironment facilitates tumor formation and maintenance. Our working group aim to
- map recurrent somatic alterations within cancer transcriptomes
- to understand tumor pathogenesis
- to identify potential targets for drug development
- characterize tumor infiltrating innate immune cells
- to elucidate the function of these cells in the tumor microenvironment
- establish biomarkers to improve early cancer diagnosis as well as therapeutic decision making
- to significantly enhance secondary prevention and outcome of cancer patients
Key publications
Gaarz A, Debey-Pascher S, Classen S, Eggle E, Gathof B, Chen J, Fan J-B, Schultze JL, Staratschek-Jox A Bead-array based microRNA expression profiling of peripheral blood and the impact of different RNA isolation approaches J Mol Diagn 2010 12: 335-344
Truong T, Hung RJ, Amos CI, Wu X, Bickeböller H, Rosenberger A, Sauter W, Illig T, Wichmann H-E, Risch A, Dienemann H, Kaaks R, Yang P, Jiang R, Wiencke JK, Wrensch M, Hansen H, Kelsey KT, Matsuo K, Tajima K, Schwartz AG, Wenzlaff A, Seow A, Ying C, Staratschek-Jox A, Nürnberg P, Stoelben E, Wolf J, Lazarus P, Muscat JE, Gallagher C, Zienolddiny S, Haugen A, van der Heijden HFM, Kiemeney LA, Isla D, Mayordomo JI, Rafnar T, Stefansson K, Zhang ZF, Chang SC, Kim JH, Hong Y-C, Duell EJ, Andrew AS, Lejbkowicz F, Rennert G, Müller H, Brenner H, Le Marchand L, Benhamou S, Bouchardy C, Teare MD, Xue X, McLaughlin J, Liu G, McKay JD, Brennan P, Spitz M. International Lung Cancer Consortium: Replication of susceptibility loci on chromosome 15q25, 5p15 and 6p21 identified in Genome-Wide Association studies J Natl Cancer Inst. 2010;102(13):959-71
Classen S, Muth C, Debey-Pascher S, Eggle D, Beyer M, Mallmann M, Rudlowski C, Zander T, Pölcher M, Kuhn W, Lahn M, Schultze J, Staratschek-Jox A Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFbR therapy. Pharmakogen Genomics 2010 20: 147-56
Staratschek-Jox A, Classen S, Gaarz A, Debey-Pascher S, Schultze JL. Blood-based transcriptomics: leukemias and beyond. Expert Review of Molecular Diagnostics, 2009, Vol. 9, No. 3, Pages 271-280.
Jungnickel B, Staratschek-Jox A, Bräuninger A, Spieker T, Wolf J, Diehl V, Hansmann ML, Rajewsky K, Küppers R. Clonal deleterious mutations in the tumor suppressor gene IkBa in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000; 191: 395-402.
Staratschek-Jox A, Kotkowski S, Belge G, Rüdiger T, Bullerdiek J, Diehl V, Wolf J. Detection of EBV genomes in Hodgkin-Reed Sternberg cells: no evidence for the persistence of integrated viral fragments in LMP1 negative cases of classical Hodgkin's disease. Am J Pathol, 2000; 156: 209-216.
Jox A, Zander T, Küppers R, Irsch J, Kanzler H, Kornacker M, Bohlen H, Diehl V, Wolf J. Somatic mutations within the untranslated regions of rearranged Ig genes in a case of classical Hodgkin's disease as a potential cause for the absence of Ig in the lymphoma cells. Blood 1999; 93: 3964-3972.
Irsch J, Nitsch S, Tesch H, Jox A, Diehl V, Hansmann ML, Rajewsky K, Küppers R, Radbruch A. Hodgkin and Reed-Sternberg cells isolated from lymph nodes are clonal populations of highly differentiated B cells. PNAS 1998; 95: 10117-10122.
Jox A, Taquia E, Vockerodt M, Pawlita M, Bullerdiek J, Diehl V, Wolf J. Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalised B-cells despite induction of chromosomal breakage and loss. Cancer Res 1998; 58: 4930-4939.
Jox A, Zander T, Diehl V, Wolf J. Clonal relapse in Hodgkin's disease. N Engl J Med 1997; 337: 499 (letter to the editor).